June 2025 in “Journal of Cosmetic Dermatology” This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.
June 2025 in “Frontiers in Pharmacology” This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.
5 citations
,
April 2025 in “Journal of the American Academy of Dermatology” This source provides an overview of expert practices for using topical and low-dose oral minoxidil in treating hair loss, highlighting how dermatologists apply existing literature to ensure safe and effective treatment.
March 2025 in “Journal of Dermatological Treatment” This study explored whether using topical minoxidil can temporarily increase hair shedding, but results are not reported.
February 2025 in “Archives of Dermatological Research” Combining PRP with topical minoxidil is most effective for hair growth in androgenetic alopecia.
November 2024 in “Actas Dermo-Sifiliográficas” In this retrospective study, oral minoxidil was found to improve the density of the frontotemporal hairline in 45.1% of patients with frontal fibrosing alopecia, with some also experiencing eyebrow and eyelash growth; however, adverse effects such as hypertrichosis were noted in 33.6% of the participants.
14 citations
,
August 2024 in “Breast Cancer Research and Treatment” This study found that oral minoxidil improved hair density in women experiencing late alopecia due to chemotherapy and/or endocrine therapy, with 74% showing clinical improvement and statistically significant increases in hair shaft density reported in those assessed with trichoscopy.
May 2024 in “Medical Journal Armed Forces India/MJAFI” This study found that low-level light therapy was as effective as 5% minoxidil for increasing hair density in men with androgenetic alopecia over six months.
May 2024 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Oral minoxidil 7.5 mg for hair loss increases heart rate but not blood pressure.
April 2024 in “JAMA dermatology” In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.
February 2024 in “Actas Dermo-Sifiliográficas” This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.
January 2024 in “Expert Opinion on Pharmacotherapy” This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.
January 2023 in “Skin appendage disorders” This study concluded that combining 5% minoxidil with microneedling was more effective in improving hair density at 6 months for adults with pattern hair loss compared to other treatments analyzed.
January 2023 in “Skin appendage disorders” This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” In this study, the authors reported that oral dutasteride at 0.5 mg/day showed a probable greater efficacy in treating male androgenetic alopecia compared to finasteride and minoxidil, but it may cause sexual dysfunction and neuropsychiatric side effects.
2 citations
,
July 2022 in “Journal of the American Academy of Dermatology” In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.
13 citations
,
February 2022 in “JAMA Dermatology” This meta-analysis reported that 0.5 mg/d of dutasteride significantly increased total hair count at 24 weeks compared to finasteride and minoxidil in men with androgenetic alopecia.
3 citations
,
January 2022 in “Journal of The American Academy of Dermatology” This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.
2 citations
,
January 2022 in “Skin appendage disorders” This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.
1 citations
,
January 2022 in “Journal of Cutaneous and Aesthetic Surgery” This study found that adding platelet-rich plasma to 5% minoxidil treatment improved hair growth outcomes in patients with androgenetic alopecia compared to minoxidil alone.
4 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” Low-dose oral minoxidil increases hair density and thickness in people with hair loss.
5 citations
,
September 2021 in “Dermatologic Therapy” In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.
16 citations
,
June 2021 in “Journal of Dermatological Treatment” This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
4 citations
,
March 2021 in “Experimental dermatology” Minoxidil increases nail growth more than biotin.
21 citations
,
March 2021 This study reviewed the literature on low-dose oral minoxidil as a primary treatment for various hair loss disorders, concluding that it is a successful and well-tolerated alternative to topical minoxidil for patients with poor adherence to other therapies.
39 citations
,
February 2021 in “Journal of The American Academy of Dermatology” In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.
2 citations
,
February 2021 in “International Journal of Research in Dermatology” The researchers reported that combining platelet-rich plasma with minoxidil showed the most improvement in androgenetic alopecia compared to other treatment groups, but also had more pain as a side effect.
5 citations
,
December 2020 in “Journal of The American Academy of Dermatology” This study observed objective improvement in androgenetic alopecia in 5 out of 6 adolescent girls treated with 2.5 mg oral minoxidil and spironolactone, and reported no adverse effects.
24 citations
,
September 2020 in “Dermatology and therapy” This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.
19 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.
12 citations
,
January 2020 in “Skin appendage disorders” Low-dose oral minoxidil effectively treats female hair loss with good safety.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.
9 citations
,
August 2019 in “Journal of The European Academy of Dermatology and Venereology” Minoxidil activation by hair enzymes predicts treatment success for female hair loss.
12 citations
,
September 2018 in “Dermatologic Therapy” This study found that 14 days of low-dose aspirin reduced the predicted response to topical minoxidil in androgenetic alopecia patients from 50% to 27%, suggesting aspirin may inhibit minoxidil efficacy.
12 citations
,
March 2018 in “Australasian Journal of Dermatology” This letter to the editor discusses the use of systemic minoxidil for loose anagen hair syndrome, noting a significant change in hair color, but reports no new study results.
27 citations
,
November 2013 in “Dermatologic Therapy” This study suggests that a hair follicle enzyme assay may predict response to minoxidil treatment for androgenetic alopecia with high sensitivity and specificity in a preliminary analysis.
212 citations
,
September 2008 in “Journal of The American Academy of Dermatology” This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.
70 citations
,
April 1990 in “Journal of The American Academy of Dermatology” Minoxidil treatment increased hair growth for up to 5 years, requiring twice daily application.
